Additionally, given the dramatic interplay between KRAS-mutated cancer cells and the immune-suppressive microenvironment, the addition of KRAS G12C inhibitors to (chemo) immunotherapy treatment constitutes a biologically sound approach [52]. The gene discussed is KRAS; the disease is cancer.